HOUSTON, Dec. 3, 2020 /PRNewswire/ -- Moleculin
Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a
clinical stage pharmaceutical company with a broad portfolio of
drug candidates targeting highly resistant tumors and viruses,
today announced that it will present animal data demonstrating
highly improved activity against acute myeloid leukemia ("AML") in
combination with the commonly used antileukemic drug Ara-C (also
referred to as "cytarabine") versus single agent at the 62nd Annual
Meeting & Exposition of the American Society for Hematology
("ASH") under the title: "High Efficacy of Liposomal Annamycin
(L-ANN) in Combination with Cytarabine in Syngeneic p53-null AML
Mouse Model."
"We are extremely encouraged by the strong pre-clinical efficacy
demonstrated by the combination of Annamycin and Ara-C against
AML," commented Walter Klemp,
Chairman and CEO of Moleculin. "While we firmly believe in the
promise and efficacy Annamycin has demonstrated as a single agent
against AML in our two current Phase 1 clinical trials, we believe
this discovery warrants further consideration to the potential
expansion of its clinical development into clinical trials for the
combination of Annamycin with Ara-C ("AnnAraC") against AML."
Mr. Klemp concluded, "The combination of Annamycin with Ara-C is
particularly intriguing considering the current first-line therapy
for AML patients is "7+3", where Ara-C is administered daily for 7
days in parallel with 3 daily doses of an anthracycline.
Substituting a currently used anthracycline such as doxorubicin
with Annamycin would be a familiar and well-practiced treatment
modality. Furthermore, the combination of Annamycin with Ara-C may
offer potential advantages given Annamycin's demonstrated lack of
cardiotoxicity and activity against tumor cells resistant to
doxorubicin. We look forward to further discussing the promise of
this combination at the 62nd Annual Meeting & Exposition of the
American Society for Hematology."
As previously announced, the study was conducted in a highly
aggressive AML mouse model where median survival, left untreated,
is approximately 13 days. Median survival in animals treated
with the combination of Annamycin and Ara-C ranged from 56 to 76
days, expanding median survival by 585%. Notably, several animals
in the study were completely cured. The Company believes these
experiments support initiation for the clinical development of the
combination of Annamycin and Ara-C in AML patients.
The study abstract, as accepted by ASH, can be viewed at:
https://ash.confex.com/ash/2020/webprogram/Paper143344.html
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical
company focused on the development of a broad portfolio of oncology
drug candidates for the treatment of highly resistant tumors and
viruses. The Company's clinical stage drugs are: Annamycin, a Next
Generation Anthracycline, designed to avoid multidrug resistance
mechanisms with little to no cardiotoxicity being studied for the
treatment of relapsed or refractory acute myeloid leukemia, more
commonly referred to as AML, WP1066, an Immune/Transcription
Modulator capable of inhibiting p-STAT3 and other oncogenic
transcription factors while also stimulating a natural immune
response, targeting brain tumors, pancreatic cancer and hematologic
malignancies, and WP1220, an analog to WP1066, for the topical
treatment of cutaneous T-cell lymphoma. Moleculin is also engaged
in preclinical development of additional drug candidates, including
other Immune/Transcription Modulators, as well as WP1122 and
related compounds capable of Metabolism/Glycosylation
Inhibition.
For more information about the Company, please visit
http://www.moleculin.com.
Forward-Looking Statements
Some of the statements in
this release are forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995, which involve risks and
uncertainties. Forward-looking statements in this press release
include, without limitation, the ability of Annamycin to show
safety and efficacy in AML patients, alone or in combination with
Ara-C and the ability of the Company to receive regulatory
authorization to begin a clinical trial for the combination of
Annamycin and Ara-C. Although Moleculin believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. Moleculin Biotech has attempted to
identify forward-looking statements by terminology including
''believes,'' ''estimates,'' ''anticipates,'' ''expects,''
''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,''
''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. These statements are
only predictions and involve known and unknown risks,
uncertainties, and other factors, including those discussed under
Item 1A. "Risk Factors" in our most recently filed Form 10-K filed
with the Securities and Exchange Commission ("SEC") and updated
from time to time in our Form 10-Q filings and in our other public
filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. We undertake
no obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events.
Contacts
James Salierno
/ Carol Ruth
The Ruth Group
973-255-8361 / 917-859-0214
jsalierno@theruthgroup.com
cruth@theruthgroup.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/moleculin-to-present-antitumor-activity-of-annamycin-in-combination-with-ara-c-in-aml-at-american-society-for-hematology-annual-conference-301185191.html
SOURCE Moleculin Biotech, Inc.